Enterin, Inc

Website
2005 Market St Ste 3125
Philadelphia, PA 19103
https://enterininc.com

Enterin, Inc is a pioneering pharmaceutical company based in Philadelphia, PA, with a groundbreaking mission to develop a revolutionary drug that repairs the dysfunctional gut-brain axis in patients suffering from neurodegenerative diseases. Their lead molecule, ENT-01, has shown promising results in preclinical models of Parkinson's Disease by displacing -synuclein aggregates and restoring normal signaling between the gut and the brain.

With recent success in meeting its primary endpoint in a Phase 2b study for Parkinson's Disease patients, Enterin's clinical data suggests that repairing the gut-brain axis can significantly enhance the quality of life for individuals affected by Parkinson's Disease and other neurodegenerative conditions, by addressing multiple non-motor symptoms. Driven by a vision of providing new hope against Parkinson's, autism, and other neurodegenerative diseases, Enterin is at the forefront of scientific research and development in this field.

Generated from the website

Also at this address

Own this business?
See a problem?

You might also like

Scientific instruments, Services, nec, nec, Real estate managers

Thermo Fisher Scientific

Our mission at Thermo Fisher is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics, deliver medicines to market and increase laboratory productivity.
Biological research

Carisma Therapeutics Inc

Carisma Therapeutics Inc. is a Philadelphia-based biotech company that is revolutionizing cancer treatment through the development of CAR-Macrophages, a groundbreaking approach to immunotherapy. By engineering monocytes and macrophages to attack tumors, Carisma's innovative cellular therapies have the potential to deliver long-term anti-tumor immunity and significantly improve patient outcomes. With a focus on leveraging advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy, Carisma's unique therapeutic approach engages both the innate and adaptive immune systems to launch a multi-pronged attack on tumors. By addressing key challenges faced by current cell therapies, such as tumor infiltration, immunosuppressive tumor microenvironments, and antigen heterogeneity, Carisma is at the forefront of developing life-changing treatments for patients with cancer and other serious disorders.Generated from the website
Assaying service

Shifa Biomedical Corp

Shifa Biomedical Corporation, based in Malvern, Pennsylvania, is a privately held biopharmaceutical company focused on the cost-effective development of drugs for cardiovascular disease. Established in 2006, the company specializes in the discovery of small molecule drugs, leveraging expertise in molecular biology, biochemistry, and medicinal chemistry. Shifa's most advanced compound targets dyslipidemia, aiming to significantly lower bad cholesterol (LDL-C) levels. By pursuing innovative approaches to regulate the PCSK9 protein, Shifa is developing a first-in-class oral small molecule therapy that could provide an effective alternative to existing injectable treatments. Generated from the website
United States›Pennsylvania›Philadelphia›Enterin, Inc

Partial Data by Infogroup (c) 2025. All rights reserved.